Rheumatology key messagesIncidence of OA presenting and diagnosed in UK primary care has not risen.New presentations of joint-pain are increasing among younger OA cohorts.

Introduction
============

Dramatic increases over the past two decades have been reported in the population burden and healthcare demand associated with OA. The Global Burden of Disease project recently estimated that crude disability-adjusted life-years attributed to OA increased by 34% between 1990 and 2015, among the largest increases seen for any non-communicable disease \[[@kex270-B1]\]. Within the same period, data available from many high-income countries show significant increases in the numbers and rates of primary hip and knee arthroplasty \[[@kex270-B2]\], over 90% of which are performed for OA \[[@kex270-B7]\]. Total direct and indirect costs associated with OA are now conservatively estimated at 0.25--0.50% gross domestic product in high-income countries \[[@kex270-B8], [@kex270-B9]\].

The rate of new cases of symptomatic OA arising in the population provides crucial information for health-policy makers, responding more quickly to changes in risk factors and being less influenced by disease duration. However, obtaining reliable incidence estimates for OA in general population cohort studies is challenging and the Global Burden of Disease project found previous estimates to be scarce and unusable \[[@kex270-B10]\]. As primary care is the first point of contact with formal healthcare services, the rate of new cases presenting and recorded in this setting (consultation incidence) provides one of the few continuous, ongoing sources of data with which to evaluate trends over time in the incidence of OA, albeit subject to the prevailing propensity to consult primary healthcare and coding systems and behaviour. To date, only two published studies worldwide, both using the same subnational administrative healthcare database in British Columbia, have estimated trends in the incidence of OA \[[@kex270-B11], [@kex270-B12]\]. These showed annual increases in crude OA incidence rates averaging 1.3--3.3% between 1996--97 and 2008--09, dropping to \<1% per year after age-standardization. In the UK, we found an increase in OA consultation incidence between 2003 and 2010 among 35--44 year olds but based on small numbers within a regional network of general practices \[[@kex270-B13]\].

Our study sought to provide the first national and subnational estimates of trends in the consultation incidence of OA and patterns of initial management between 1992 and 2013 in the UK using a large nationally representative primary care database.

Methods
=======

Study design and setting
------------------------

We undertook a descriptive study using routinely collected longitudinal data from the UK Clinical Practice Research Datalink (CPRD), which contains computerized primary care records from general practices covering around 7% of the UK population \[[@kex270-B14]\]. CPRD records anonymized patient demographics, consultations, diagnoses, prescriptions and tests from primary care, and also includes those referrals to specialists, hospital admissions and diagnoses made in secondary care, reported back to the general practitioners and recorded by them within their computerized records. CPRD has reported high validity for a range of diagnoses \[[@kex270-B15]\]. The study was approved by the independent scientific advisory committee for CPRD research (protocol reference: 14_09010_193 R). No further ethical permissions were required for the analyses of these anonymized patient level data.

Definition of incident cases and at-risk population
---------------------------------------------------

Several algorithms have been used in previous studies, predominantly from Canada and the USA, to define OA cases in electronic health record and administrative databases \[[@kex270-B16], [@kex270-B17]\]. In line with a Swedish report \[[@kex270-B18]\], we chose case definitions requiring a single record of a relevant code within the primary care electronic health record within a calendar year of interest. Less restrictive definitions such as these have been used in previous studies of OA incidence in Canada \[[@kex270-B11], [@kex270-B12], [@kex270-B19], [@kex270-B20]\], the Netherlands \[[@kex270-B21]\] and Spain \[[@kex270-B24]\], and of OA consultation prevalence in UK primary care \[[@kex270-B25], [@kex270-B26]\] and have generally higher sensitivity but lower specificity than more restrictive algorithms requiring multiple records \[[@kex270-B17]\].

Using established Read code lists \[[@kex270-B26]\] (code lists available from [www.keele.ac.uk/mrr](http://www.keele.ac.uk/mrr)) we defined cases of OA in two ways: firstly, to maximize sensitivity and capture the greatest number of new consulting cases of OA, cases were defined as having either at least one consultation with a recorded diagnosis of OA or, in adults aged over 45 years, at least one consultation with a recorded peripheral joint pain symptom code affecting the knee, hip and hand/wrist likely to reflect OA (clinical OA); secondly, cases of OA were defined more narrowly as having at least one consultation with a recorded diagnosis of OA (OA). We excluded cases with a record of a systemic inflammatory disease, spondyloarthropathy or crystal disease in the previous 3 years or following 1 year, or a record of another specific non-OA diagnosis (soft-tissue disorders, other bone/cartilage diseases) at the same joint in the 6 months before or after the recorded OA/joint pain consultation.

The at-risk population in each calendar year was defined as all patients with complete registration history within CPRD in the previous 3 calendar years and no OA consultation in that period. Incident cases among the at-risk population in each calendar year were defined as a coded record during the year ([supplementary Fig. S1](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* Online).

Descriptive characteristics and management of incident cases
------------------------------------------------------------

To explore the changing characteristics of incident cases of OA and their pharmacological management we described the age and gender distribution of cases, and the proportion of cases with: ⩾5 and ⩾10 British National Formulary chapters prescribed in the 1 year prior to the diagnosis date (a measure of multimorbidity) \[[@kex270-B27]\]; a record of an X-ray referral within 30 days before or after diagnosis date; a prescription for an NSAID, cyclooxygenase-2 (COX-2) inhibitor, or opioid analgesic within 14 days after diagnosis date. Opioid analgesics were sub-classified into weak (e.g. codeine 8 mg + paracetamol), moderate (e.g. dihydrocodeine 20 mg), strong (e.g. tramadol 50 mg) and very strong (e.g. oxycodone) \[[@kex270-B28]\].

Statistical analysis
--------------------

Patients consulting for OA in a given year will be a mixture of new (incident) cases and ongoing (prevalent) cases. We used the run-in period method to look back in the medical record to exclude prevalent cases and to define the at-risk population. Run-in periods from 1 to 10 years were compared using time series models and 3 years was selected as optimal in this data source for OA \[[@kex270-B13]\]. Annual crude incidence was defined by incidence density as the number of incident cases divided by observed person-time in each calendar year with persons censored by death, moving practice, or OA diagnosis ([supplementary Fig. S1](#sup1){ref-type="supplementary-material"} and [supplementary Table S1](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* Online). Annual incidence was stratified by gender, age group (35--44, 45--54, 55--64, 65--74, 75--84, 85+ years) and geographical region. Age--sex-standardized incidence rates were estimated using the mid-2013 UK population as the standard ([supplementary Methods](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* Online) with 95% CIs estimated by Poisson regression. We estimated the total numbers of newly diagnosed cases of OA and clinical OA presenting to UK primary care in 2013 by multiplying the incidence rates in 2013 from this study and estimated size of the at-risk population in the UK in 2013 based on mid-2013 population size and 6.9% population coverage by CPRD in the same year \[[@kex270-B14]\].

To explore age-period-cohort effects, we first described and plotted the age-stratified incidence of clinical OA in 14 birth cohorts: cohort-1915, cohort-1920, cohort-1925, cohort-1930, cohort-1935, cohort-1940, cohort-1945, cohort-1950, cohort-1955, cohort-1960, cohort-1965, cohort-1970 and cohort-1975. We then modelled age-period-cohort effects (in calendar years) on clinical OA and OA from 1992 to 2013. Two approaches to age-period-cohort analysis were used to provide a robust check on results. OA and clinical OA incidence rates were estimated using parametric smooth functions based on natural cubic splines with knots each for age, period and cohort variables to detect nonlinear effects \[[@kex270-B29]\]. In the analysis of period effect, the calendar year of 2000 was used as the period referent group.

Sensitivity analyses
--------------------

Incidence estimates are sensitive to the length of run-in period \[[@kex270-B20], [@kex270-B30]\] and so we repeated the analyses using a 10 year run-in period \[[@kex270-B20]\]. General practice membership of CPRD is dynamic (i.e. open to practices joining and leaving) and so to evaluate the potential impact of this, we estimated the incidence in four fixed practice cohorts that joined at different periods but contributed continuously thereafter to 2013: cohort 1 (102 practices providing incidence estimates from 1994 to 2013), cohort 2 (73 practices, 2000--13), cohort 3 (163 practices, 2004--13), cohort 4 (130 practices, 2009--13) ([supplementary Table S2](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* Online). Data management and analysis were performed using Stata MP Software V14.1 (StataCorp, College Station, TX, USA).

Results
=======

We analysed 1 716 253 incident cases of clinical OA and 432 163 incident cases of OA recorded between 1992 and 2013. In 2013, age--sex standardized incidence rates for clinical OA and OA were 40.5 (95% CI: 40.3, 40.7) and 6.3 (95% CI: 6.2, 6.4) per 1000 person-years, respectively. For both case definitions, age-standardized incidence rates were higher among women than men \[46.2 (45.9, 46.5) *vs* 35.0 (34.7, 35.3) and 7.6 (7.5, 7.7) *vs* 4.9 (4.8, 5.0)\], and peaked at 75--84 years in women and in men. The mean age of incident cases of clinical OA was 52.7 years (56.1% women) compared with 67.2 years (61.6% women) among incident cases of OA. A record of an X-ray referral at time of diagnosis was found in 16.4% of clinical OA cases and 22.0% of incidence OA cases. Multimorbidity was common, with 51.0% of incident cases of clinical OA and 74.9% of OA cases prescribed ⩾5 unique categories of drug in the preceding year (⩾10 drug categories: 22.5% and 40.2%, respectively).

Joint-specific standardized incidence estimates in 2013 for knee OA were as follows: clinical knee OA: 19.7 (overall), 20.8 (women), 18.5 (men); knee OA: 1.9, 2.1, 1.6; clinical hip OA: 8.0, 10.4, 5.5; hip OA: 1.3, 1.6, 0.9; clinical hand OA: 4.3, 5.2, 3.3; hand OA: 2.5, 3.5, 1.5. Similar patterns of age-specific incidence were found for clinical knee OA, knee OA, clinical hip OA and hip OA: a progressive increase from age 35--44 years, peaking at 75--84 years in men and women. A different age-specific pattern was observed for clinical hand OA and hand OA, which showed an early peak in age group 55--64 years in women.

Temporal trend in OA incidence and management, 1992--2013: descriptive analyses
-------------------------------------------------------------------------------

Annual age--sex standardized incidence rates of diagnosed OA showed a small increase over the period 1992--2004 but decreased thereafter ([Table 1](#kex270-T1){ref-type="table"}). The annual standardized incidence rates of clinical OA were also largely stable from 1992 to 2000 but then increased markedly to 2009 after which they dropped slightly. Similar trends for both case definitions were observed in women and men and in each age stratum ([Fig. 1](#kex270-F1){ref-type="fig"}). T[able]{.smallcaps} 1Primary care consultation incidence of OA: UK, 1992**--**2013YearClinical OAOACasesPerson-yearsCrude incidenceAge**--**sex-standardized incidenceCasesPerson-yearsCrude incidenceAge**--**sex-standardized incidenceIR (95% CI)IR (95% CI)IR (95% CI)IR (95% CI)1992231873 49131.5 (30.3, 32.8)29.2 (28.8, 29.5)73382 5378.9 (8.2, 9.5)8.1 (7.9, 8.2)199311 101322 99034.4 (33.7, 35.0)30.8 (30.5, 31.2)3323379 3438.8 (8.5, 9.1)7.7 (7.5, 7.8)199420 590648 33831.8 (31.3, 32.2)28.4 (28.1, 28.7)6064737 3388.2 (8.0, 8.4)7.0 (6.9, 7.2)199524 091774 07331.1 (30.7, 31.5)27.9 (27.6, 28.2)7432889 6948.4 (8.2, 8.5)7.2 (7.0, 7.3)199628 019893 21031.4 (31.0, 31.7)28.3 (28.0, 28.6)91111 028 8588.9 (8.7, 9.0)7.7 (7.5, 7.8)199731 163974 39232.0 (31.6, 32.3)28.8 (28.6, 29.1)10 3501 110 6279.3 (9.1, 9.5)8.1 (8.0, 8.2)199833 1271 059 20831.3 (30.9, 31.6)28.4 (28.1, 28.6)11 2661 212 8769.3 (9.1, 9.5)8.1 (7.9, 8.2)199933 8201 127 81330.0 (29.7, 30.3)27.2 (27.0, 27.4)12 1011 280 6079.4 (9.3, 9.6)8.2 (8.1, 8.3)200039 5291 301 15130.4 (30.1, 30.7)27.2 (27.0, 27.4)14 0211 501 0329.3 (9.2, 9.5)7.9 (7.8, 8.0)200148 7231 510 68732.3 (32.0, 32.5)28.7 (28.5, 28.8)16 7311 735 2599.6 (9.5, 9.8)8.0 (8.0, 8.1)200262 7601 766 50235.5 (35.2, 35.8)31.3 (31.2, 31.5)19 3262 029 5079.5 (9.4, 9.7)7.9 (7.8, 8.0)200383 8762 117 34339.6 (39.3, 39.9)35.0 (34.8, 35.2)24 2692 445 0429.9 (9.8, 10.1)8.3 (8.3, 8.4)2004102 5182 427 29942.2 (42.0, 42.5)37.3 (37.1, 37.5)28 4382 780 33110.2 (10.1, 10.3)8.6 (8.6, 8.7)2005112 6892 662 77742.3 (42.1, 42.6)37.4 (37.3, 37.6)30 8283 092 89210.0 (9.9, 10.1)8.5 (8.4, 8.6)2006122 6102 861 32042.9 (42.6, 43.1)37.8 (37.6, 37.9)30 6633 318 0659.2 (9.1, 9.3)7.8 (7.7, 7.9)2007132 4372 966 79944.6 (44.4, 44.9)39.5 (39.3, 39.7)31 1743 450 5339.0 (8.9, 9.1)7.6 (7.6, 7.7)2008141 1773 015 42346.8 (46.6, 47.1)41.6 (41.4, 41.8)32 3643 525 5839.2 (9.1, 9.3)7.8 (7.7, 7.9)2009145 5503 005 68848.4 (48.2, 48.7)42.9 (42.7, 43.1)31 8893 549 7089.0 (8.9, 9.1)7.6 (7.5, 7.7)2010139 7842 964 79447.1 (46.9, 47.4)41.3 (41.2, 41.5)30 0043 534 1968.5 (8.4, 8.6)7.1 (7.0, 7.2)2011138 4602 914 14047.5 (47.3, 47.8)41.4 (41.2, 41.6)29 4483 495 6978.4 (8.3, 8.5)7.0 (7.0, 7.1)2012133 4092 863 87346.6 (46.3, 46.8)41.2 (41.0, 41.4)27 4833 437 8978.0 (7.9, 8.1)6.7 (6.7, 6.8)2013128 5022 695 58347.7 (47.4, 47.9)40.5 (40.3, 40.7)25 1453 191 3317.9 (7.8, 8.0)6.3 (6.2, 6.4)[^1]

![Age-specific temporal trend in incidence rate of OA, by gender: UK, 1992--2013\
Solid line and dotted line represent the incidence rates for clinical OA and OA, respectively. Light grey triangle, dark grey diamond and black circle indicate estimates for women, men and all, respectively.](kex270f1){#kex270-F1}

The trends of clinical OA and OA incidence rates differed by joint. In keeping with the trend seen for clinical OA in general, both clinical knee OA and clinical hip OA increased markedly from 2000 reaching a plateau in 2009--13 whereas clinical hand OA increased steadily from 2000 to 2013. Knee OA and hip OA remained relatively stable from 2000 to 2013, while hand OA increased steadily over the same period ([supplementary Table S3](#sup1){ref-type="supplementary-material"} and [supplementary Fig. S2](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* Online). The fluctuating incidence of hip OA and hand OA we interpret as reflecting variable use joint-specific OA codes before 2000.

The increase in incidence of clinical OA between 2000 and 2009 was more marked in regions with comparatively low incidence rates in 2000, such that regional variation was reduced in 2009 ([Fig. 2;](#kex270-F2){ref-type="fig"}[supplementary Fig. S3](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* Online).

###### 

Region-specific temporal trend in incidence rate of OA, by gender: UK, 1992--2013

Left panel: clinical OA; right panel: OA. In each plot, the black line represents the trend of overall incidence in the specific region; the grey line represents the general trend of overall incidence in the UK; the bubble size in each calendar year is determined by the proportion of the overall at-risk population within that region.
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In our sensitivity analyses, similar trends of incidence rates for both clinical OA and OA were observed when the run-in period was extended to 10 years ([supplementary Fig. S4](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* Online), but with lower incidence for clinical OA suggesting that a run-in period longer than 3 years is needed to identify first consultation for this case definition (clinical OA: 32.9/1000 person-years; OA: 6.6/1000 person-years, in 2013). Based on this conservative 10-year run-in period, we estimate that in 2013 approximately 1 209 594 new cases of clinical OA presented to UK primary care, of whom 432 804 received the diagnosis of OA. A similar trend in incidence rate was also identified when analysis was restricted to the four fixed cohorts of practices who contributed to incidence estimates continuously from joining to 2013 ([supplementary Fig. S5](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* Online).

Temporal trend in OA incidence, 1992--2013: age-period-cohort analyses
----------------------------------------------------------------------

[Figure 3](#kex270-F3){ref-type="fig"} ([supplementary Fig. S6](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* Online) shows plots of clinical OA and OA incidence by age for the six selected birth cohorts. At virtually every age, later birth cohorts had higher rates of incidence of clinical OA than earlier birth cohorts. Cohorts born after the mid-1950s showed an increased incidence of clinical OA particularly in females while a decline in the incidence of OA was seen ([Fig. 4;](#kex270-F4){ref-type="fig"}[supplementary Fig. S7](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* Online).

![Age-specific incidence rate of OA, by selected birth cohorts: UK, 1992--2013\
Left panel: clinical OA; right panel: OA. Small circle indicates the birth cohort 1925; small open triangle indicates the birth cohort 1935; small open circle indicates the births cohort 1945; plus symbol indicates the birth cohort 1955; large solid triangle indicates the birth cohort 1965; large solid circle indicates the birth cohort 1975.](kex270f3){#kex270-F3}

![Age-period-cohort influences on OA incidence, by gender: UK, 1992--2013\
Left panel: clinical OA; right panel: OA. The age-specific rates (dark grey curve) are cross-sectional, referring to 2000 (open circle). Adjusted risk ratio (black curve) represents the period effect in 1992**--**2013, with 2000 as the reference. Adjusted risk ratio (light grey curve) represents the birth cohort from 1910 to 1980.](kex270f4){#kex270-F4}

Trends in characteristics and prescribed analgesia among incident cases of OA, 1992--2013
-----------------------------------------------------------------------------------------

All forms of analgesia were more likely to be prescribed to incident cases of OA than cases with clinical OA. Cox-2 prescriptions among incident cases increased in 1999--2004 and declined sharply afterwards (coinciding with withdrawal of rofecoxib \[[@kex270-B31]\] and safety advice on all selective Cox-2 inhibitors issued by the Medicines & Healthcare Products Regulatory Agency \[[@kex270-B32]\]). The proportion of incident cases receiving a prescription for oral NSAID also declined after 2004 with weak combination opioids becoming the most common class of prescribed analgesia from 2005 onwards. The proportion of incident cases of OA receiving a prescription for very strong opioids increased from 0.1% in 2004 to 0.5% in 2013 for clinical OA; 0.6% in 2006 to 1.2% in 2013 for OA ([Table 2](#kex270-T2){ref-type="table"}). T[able]{.smallcaps} 2Analgesic prescriptions[^a^](#tblfn2){ref-type="table-fn"} among incident cases of OA: UK, 1992--2013YearIncident cases, nMean age, yearsFemale, %Prescribed analgesia, %COX-2NSAIDsAnalgesicsWeak combination opioidsModerate combination opioidsStrong combination opioidsVery strong single opioidsCase definition: clinical OA1992231852.358.30.019.914.00.010.10.1199311 10151.957.50.021.314.00.10.10.1199420 59052.557.70.020.914.10.040.10.04199524 09153.258.40.020.415.60.10.10.1199628 01953.854.40.021.215.70.10.10.1199731 16353.958.00.021.515.40.20.10.1199833 12754.158.20.020.715.40.20.10.1199933 82054.358.40.320.014.50.20.10.1200039 52954.357.61.919.014.70.20.10.1200148 72354.657.83.519.314.30.30.040.1200262 76054.157.55.519.714.40.30.040.1200383 87653.757.16.619.813.80.30.10.12004102 51853.657.37.020.714.00.30.10.12005112 68953.656.80.919.414.20.40.10.22006122 61053.156.20.918.713.70.30.10.32007132 43753.056.01.018.614.10.40.10.32008141 17752.856.20.917.214.00.30.10.42009145 55052.755.60.816.614.00.30.10.42010139 78452.655.40.716.213.90.30.10.52011138 46053.056.00.515.614.20.30.10.52012133 40952.656.00.415.314.00.30.10.52013128 50252.756.10.414.914.00.30.10.5Case definition: OA199273364.259.60.022.918.10.00.10.01993332365.360.70.025.620.10.00.10.11994606465.462.70.026.019.60.00.10.01995743265.763.20.023.721.80.10.00.11996911166.061.90.025.822.70.20.10.0199710 35066.163.50.026.022.60.20.10.1199811 26666.362.60.024.323.00.30.00.1199912 10166.362.80.724.321.40.30.00.0200014 02166.262.43.824.622.10.40.10.0200116 73166.562.66.925.421.30.40.10.1200219 32666.562.910.327.221.60.60.10.1200324 26966.662.812.126.921.60.60.10.2200428 43866.663.812.427.021.80.60.10.2200530 82866.862.61.821.022.60.90.10.4200630 66366.962.71.518.221.70.70.10.6200731 17466.861.81.717.521.50.70.20.7200832 36466.762.01.616.021.20.70.10.9200931 88966.661.21.514.921.30.70.21.1201030 00466.761.21.314.220.60.70.21.3201129 44867.061.51.113.520.90.60.21.2201227 48366.861.30.912.920.20.60.11.3201325 14567.261.60.612.519.70.50.21.2[^2]

Discussion
==========

OA is a significant and growing problem worldwide whether measured in terms of population burden or joint arthroplasty procedures. Primary care occupies a critical role in the response of healthcare systems to this public health challenge \[[@kex270-B33]\]. Our UK national study found that the incidence of clinical OA presenting to primary care---measured broadly as new cases of diagnosed OA and peripheral joint pain in patients aged over 45 years---increased between 1992 and 2013, reaching 40.5/1000 person-years in 2013. The majority of this increase was seen between 2000 and 2009 and affected all ages, birth cohorts and geographical regions, particularly those regions with the lowest rates before 2000. Beyond this strong period effect, however, we saw a continued increase in the consultation incidence of clinical OA for successive cohorts born after the mid-1950s, particularly women. In contrast, with the exception of hand OA, we observed no increase in the annual incidence of diagnosed cases of OA over the same period. Instead, rates declined from a high of 8.6/1000 person-years in 2004 to 6.3 in 2013.

Age-standardized incidence rates for physician-diagnosed OA reported in previous studies of health administrative and primary care electronic health record data in Canada \[[@kex270-B11], [@kex270-B12], [@kex270-B19], [@kex270-B20], [@kex270-B30]\], the Netherlands \[[@kex270-B21]\] and the UK \[[@kex270-B13]\] range between 5 and 17 cases per 1000 person-years. It is well-recognized that such rates are sensitive to the specific case definition adopted, the length of run-in period used to exclude prevalent cases, the capture and linkage of hospital data and other databases, population structure and the particular characteristics and incentives for coding behavior within different healthcare systems and databases. Against previously reported incidence rates, those in the current study for diagnosed OA in CPRD are comparatively low, something we also observed for estimates of consultation prevalence of musculoskeletal disorders \[[@kex270-B25]\]. It is notable that the average age at diagnosis of OA was 67.2 years in 2013---only 1 or 2 years less than the mean age of patients undergoing primary hip or knee arthroplasty for OA in the UK \[[@kex270-B34]\]. Attending only to consultations recorded with the diagnostic code of OA may therefore provide a late and partial view of demand for primary care in the UK. Incidence rate estimates for clinical OA are substantially higher, required a longer run-in period to exclude prevalent cases, showed stronger period effects, and most likely represent the upper limits of new cases of OA presenting to primary care. Importantly, observed trends in incidence rates of OA and clinical OA in the current study were not sensitive to the length of run-in period or to the dynamic nature of practice membership within CPRD over time.

An increasing incidence of clinical OA among recent birth cohorts is consistent with similar trends in obesity \[[@kex270-B35], [@kex270-B36]\]---a potent risk factor for OA \[[@kex270-B37], [@kex270-B38]\]---and the increased reporting and presentation of painful symptoms in general. In contrast, the relative stability of diagnosed OA rates argues against there having been major changes in the incidence of more severe OA in recent decades. In one of the few population-based studies of changes in the prevalence of knee OA symptoms and radiographic changes in the USA, Nguyen *et al.* \[[@kex270-B39]\] found substantial increases in self-reported knee pain but not radiographic OA between 1974 and 1994 after adjusting for changing distribution of BMI. Nevertheless, the observed trend of increasing incidence of clinical OA in recent birth cohorts may translate into future increased demand for joint arthroplasty beyond that driven by demographic change, and in the context of changing indications of the proportion of all clinical OA who may benefit from surgery or be referred for this.

The rising use of prescribed opioid analgesia is not limited to OA but has been previously highlighted in the UK and other high-income countries \[[@kex270-B28], [@kex270-B40]\]. This trend needs to be seen also in the context of rising levels of multimorbidity and co-pharmacy among cases of OA. We found that new cases of OA will often have multiple different prescribed medicines. While the definition used in our study could include short-term prescriptions and different analgesic prescriptions, nevertheless we interpret these data as consistent with the findings of Melzer *et al.* \[[@kex270-B45]\] who reported high and rising prevalence of polypharmacy and multimorbidity in patients aged \>65 years, and particularly aged \>85 years in the period 2003--04 to 2011--12. This trend is likely to present increasing challenges for the selection and use of pharmacological, non-pharmacological and surgical treatments for OA. The temporal pattern of paracetamol use was not presented in this study because a large fraction of paracetamol use would be from over-the-counter supply and the prescribed supply would largely reflect the age of exemption from prescription costs. Less well-documented is the continued high use of radiographic investigations despite guidelines over the past two decades consistently highlighting their limited role in the assessment and diagnosis of OA \[[@kex270-B46]\]. Utilization of MRI to aid OA diagnosis was not part of our original protocol submitted to, and approved, by the Independent Scientific Advisory Committee: the validity of coding MRI has yet to be investigated in CPRD and this is perhaps a future study. We also refrained from analysing the temporal pattern of BMI among incident cases, because in CPRD, the completeness of BMI changed over time, that is, 37% in 1990--94 and 77% in 2005--11, and varied by female and age (higher in female gender and increased with age) \[[@kex270-B14]\]. The trend of BMI/obesity among incident OA cases would be significantly affected by the completeness of BMI, which is almost certainly missing not at random (i.e. the reason for not having a recorded BMI is related to your BMI; for example, only people who are overweight or have some other risk factors or health conditions will have their BMI recorded).

Some additional limitations should be mentioned. The true incidence of joint-specific OA will be underestimated due to practitioners using general codes (e.g. OA), particularly for patients presenting with multiple affected joints. Our estimates of knee OA in particular are low by comparison with other published primary care incidence rates \[[@kex270-B24]\]. We used a stand-alone primary care database and in other health conditions the importance of linked secondary care records for complete capture of cases has been demonstrated \[[@kex270-B49]\]. The proportion of cases of OA diagnosed in secondary care and not recorded in the CPRD primary care database is not known but in the Canadian studies, physician claims accounted for 80--90% of cases \[[@kex270-B30]\] and the general practitioner for 84% of all cases identified from visits to health professionals \[[@kex270-B11]\]. A similar contribution from secondary care diagnoses to OA prevalence estimates was seen in Swedish healthcare registry data \[[@kex270-B26]\]. Cases diagnosed as OA in secondary care are nevertheless likely to be captured within the primary care health record using our broader definition of clinical OA.

Conclusions
-----------

Between 1992 and 2013, the age-standardized incidence of all clinical OA increased while that of diagnosed OA remained stable or even declined. Amid strong period effects, cohorts born after the mid-1950s are showing higher incidence rates of clinical OA than previous generations at the same age. Prescribed opioid analgesia and plain radiography appear to be over-used.

Supplementary Material
======================

###### 

Click here for additional data file.

The authors would like thank Prof. Peter Croft and Ingemar Petersson for insightful comments on the draft manuscript. G.P. and K.P.J. would like to thank Public Health England for their Honorary Academic Consultant Contracts.

*Funding*: This research was funded by infrastructure support funds from North Staffordshire Primary Care Research Consortium.

*Disclosure statement*: The authors have declared no conflicts of interest.

Supplementary data
==================

[Supplementary data](#sup1){ref-type="supplementary-material"} are available at *Rheumatology* Online.

[^1]: Incidence rates are presented as age--sex standardized incidence (95% CI) per 1000 person-years, with mid-2013 UK population as standard population. IR: incidence rate.

[^2]: Prescriptions issued within 14 days after incident OA consultation.
